NCT06775912View on ClinicalTrials.gov

Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

January 15, 2025

Primary Completion Date

January 1, 2027

Study Completion Date

June 1, 2027

Conditions
SLESystemic SclerosisIIMNMOSDMSMGANCA Associated Vasculitis (AAV)
Interventions
DRUG

RD06-05 CART Cell Injection

CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide

Trial Locations (1)

222000

RECRUITING

The First People's Hospital of Lianyungang, Lianyungang

All Listed Sponsors
lead

Nanjing Bioheng Biotech Co., Ltd.

INDUSTRY